NLS Pharmaceutics announced that the FDA has accepted its investigational new drug application (IND) for Quilience, the company‘s drug candidate for the treatment of narcolepsy.

The IND enables NLS to initiate its Phase 2a trial to assess the safety and efficacy of Quilience, which the company expects to commence next month.

The proposed multi-center study, to be conducted in both the U.S. and Europe, is expected to enroll 60 patients.

Get the full story at